BiotechTube
NeuroSigma

NeuroSigma

Los Angeles, United States· Est.
neurosigma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.1M

Overview

NeuroSigma is a commercial-stage medical device company pioneering external trigeminal nerve stimulation (eTNS) for neuromodulation. Its flagship Monarch eTNS System holds FDA clearance for pediatric ADHD as a non-invasive, non-pharmacological treatment, representing a first-in-class device. The company is targeting large neurological markets, including epilepsy and depression, with its patented platform. Backed by clinical data from multiple trials and an extensive patent portfolio, NeuroSigma aims to provide accessible, evidence-based neurotherapeutics.

NeurologyPsychiatry

Technology Platform

Non-invasive external Trigeminal Nerve Stimulation (eTNS) delivered via a wearable pulse generator and forehead electrode to modulate brain activity.

Funding History

2
Total raised:$17.1M
Grant$2.1M
Series A$15M

Opportunities

The primary opportunity lies in expanding the FDA clearance of the eTNS platform into large, underserved markets like drug-resistant epilepsy and major depressive disorder, which represent multi-billion dollar addressable markets.
Additionally, the non-invasive, non-pharmacological nature of the therapy positions it favorably in the growing demand for alternative neurological treatments with fewer side effects.

Risk Factors

Key risks include commercial execution challenges in launching a novel medical device, including physician adoption and insurance reimbursement.
Significant pipeline risk exists as expansion into larger indications requires successful and costly clinical trials and regulatory approvals.
The company also faces financial risk as a private entity needing to secure capital for growth.

Competitive Landscape

NeuroSigma competes in the neuromodulation space, facing competition from invasive devices (e.g., VNS, DBS for epilepsy/depression) and pharmaceutical standards of care. Its primary differentiator is non-invasiveness. It may face future competition from other non-invasive neuromodulation technologies (e.g., transcranial magnetic stimulation for depression) and potential new entrants developing similar external nerve stimulation devices.

More companies in Neuroscience & CNS →More companies in United States →